BioSpace News Archive

Sunshine Biopharma Inc. today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock.

iSpecimen Inc. today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group and M-Vest on Wednesday, January 25, 2023.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint.

AVAIL SCIENTIFIC (OTC PINK: MOBO ) is pleased to announce it is entering into a letter of intent (LOI) to acquire Florida based Relai Neuro LLC which provides Neurological testing and data management.

Zhongchao Inc. today announced that Zhongxin Medical Technology Co., Ltd. (“Zhongxin”), one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements, launched the Medication Management Assistance Mini Program on WeChat.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group,announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.

Aprea Therapeutics, Inc. announced that it will participate in the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts from January 24 – January 26, 2023.

Outlook Therapeutics, Inc. announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence.

Daxor Corporation, the global leader in blood volume measurement technology, announces joining the Heart Failure Society of America as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure.

DM Clinical Research, a national network of clinical trial sites, has opened its first research location in the Boston metropolitan area and Massachusetts.